These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27178030)

  • 1. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
    Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
    Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines.
    Nowakowski A; Cybulski M; Śliwczyński A; Chil A; Teter Z; Seroczyński P; Arbyn M; Anttila A
    BMC Cancer; 2015 Apr; 15():279. PubMed ID: 25879466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain.
    Castellsagué X; Rémy V; Puig-Tintoré LM; de la Cuesta RS; Gonzalez-Rojas N; Cohet C
    J Low Genit Tract Dis; 2009 Jan; 13(1):38-45. PubMed ID: 19098605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.
    Giorgi Rossi P; Ricciardi A; Cohet C; Palazzo F; Furnari G; Valle S; Largeron N; Federici A
    BMC Public Health; 2009 Feb; 9():71. PubMed ID: 19243586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
    Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
    Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
    J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of screening and treatment of cervical dyskaryosis in Germany.
    Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
    Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
    Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
    Syrjänen K
    Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
    Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
    PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and costs of cervical intraepithelial neoplasia in the Korean population.
    Chang HK; Seo SS; Myong JP; Yu YL; Byun SW
    J Gynecol Oncol; 2019 May; 30(3):e37. PubMed ID: 30887758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
    Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.
    Flores Y; Shah K; Lazcano E; Hernández M; Bishai D; Ferris DG; Lörincz A; Hernández P; Salmerón J;
    Salud Publica Mex; 2002; 44(4):335-44. PubMed ID: 12216521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health and economic burden of HPV-related diseases in Singapore.
    Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
    Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.
    Benard VB; Castle PE; Jenison SA; Hunt WC; Kim JJ; Cuzick J; Lee JH; Du R; Robertson M; Norville S; Wheeler CM;
    JAMA Oncol; 2017 Jun; 3(6):833-837. PubMed ID: 27685805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic implications of adding HPV tests to the routine cytology follow-up and management of patients with histologically defined cervical intraepithelial neoplasia grade 1.
    Gamzu R; Almog B; Levin I; Fainaru O; Niv J; Lessing JB; Bar-Am A
    Gynecol Oncol; 2002 Aug; 86(2):129-33. PubMed ID: 12144817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.